Top

Annals of Nuclear Medicine

Published in:

01-09-2009 | Original Article

A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity

Authors: Kentaro Inoue, Ryoi Goto, Ken Okada, Shigeo Kinomura, Hiroshi Fukuda

Published in: Annals of Nuclear Medicine | Issue 7/2009

Abstract

Objective

In clinical positron emission tomography (PET) studies for oncology, it is occasionally required to differentiate a diffuse increase in bone marrow (BM) F-18 fluoro-2-deoxyglucose (FDG) uptake due to the involvement of malignancy or hematopoietic disease and that due to the administration of hematopoietic cytokines, an inflammation reaction, or stimulation by some types of malignancy. The objectives of this study were to clarify the relationships between BM F-18 FDG uptake and blood parameters as well as age, and also to determine the degree of F-18 FDG accumulation that constitutes an abnormal level referring to blood parameters.

Methods

Records of 65 patients, 32 with benign diseases and 33 with malignancies without metastasis in bone and liver until a half year after the PET examination, were analyzed retrospectively. Regions of interest were placed on the liver and the lower thoracic and lumbar vertebrae to measure the standardized uptake value (SUV), and vertebral SUVs were averaged as the BM SUV_mean. The BM SUV_mean was divided by the liver SUV to calculate the BM/liver ratio. The relationships among the BM SUV_mean, or BM/liver ratio, and blood parameters and age were tested using multiple regression analysis.

Results

In both patients with and without malignancy, a multiple regression model using the BM/liver ratio showed a higher coefficient of determination value than that using the BM SUV_mean, indicating that the correction by the liver SUV reduced the interindividual variation in the BM SUV_mean. The BM/liver ratio was negatively correlated with age (β = −0.41 and −0.43, respectively) and positively correlated with serum C-reactive protein (CRP) level (β = 0.39 and 0.46, respectively) in both groups of patients. Every patient with benign disease who had a ratio greater than or equal to 1 had an increased CRP level.

Conclusions

The BM F-18 FDG uptake depends on the patient’s age and serum CRP level, both with and without malignancy. A BM F-18 FDG uptake greater than or equal to that of the liver may indicate BM activation.

Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol. 1997;169:1675–80.PubMed

Prevost S, Boucher L, Larivee P, Boileau R, Benard F. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med. 2006;47:559–65.PubMed

Cicone F, Loose D, Deron P, Vermeersch H, Signore A, Van de Vyvere F, et al. Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck. Nucl Med Commun. 2008;29:431–5.PubMedCrossRef

Van de Wiele C, VandeVyver F, Debruyne C, Philippe J, van Meerbeeck JP. FDG uptake by the bone marrow in NSCLC patients is related to TGF-beta but not to VEGF or G-CSF serum levels. Eur J Nucl Med Mol Imaging. 2008;35:519–22.PubMedCrossRef

Fan C, Hernandez-Pampaloni M, Houseni M, Chamroonrat W, Basu S, Kumar R, et al. Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography. Mol Imaging Biol. 2007;9:300–7.PubMedCrossRef

Murata Y, Kubota K, Yukihiro M, Ito K, Watanabe H, Shibuya H. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol. 2006;33:999–1004.PubMedCrossRef

Ramos CD, Erdi YE, Gonen M, Riedel E, Yeung HW, Macapinlac HA, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001;28:155–64.PubMedCrossRef

Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173–80.PubMed

Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMed

10.

Iozzo P, Geisler F, Oikonen V, Maki M, Takala T, Solin O, et al. Insulin stimulates liver glucose uptake in humans: an 18F-FDG PET Study. J Nucl Med. 2003;44:682–9.PubMed

11.

Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2009; 11(2):118–22

12.

Ricci C, Cova M, Kang YS, Yang A, Rahmouni A, Scott WW Jr, et al. Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study. Radiology. 1990;177:83–8.PubMed

13.

Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med. 2004;29:161–3.PubMedCrossRef

14.

Plantade A, Montravers F, Selle F, Izrael V, Talbot JN. Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy. Clin Nucl Med. 2003;28:771–2.PubMedCrossRef

15.

Kao PC, Shiesh SC, Wu TJ. Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci. 2006;36:163–9.PubMed

16.

Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. Am J Epidemiol. 2001;153:1183–90.PubMedCrossRef

17.

Mauer AM, Athens JW, Ashenbrucker H, Cartwright GE, Wintrobe MM. Leukokinetic studies. II. A method for labeling granulocytes in vitro with radioactive diisopropylfluorophosphate (DFP). J Clin Invest. 1960;39:1481–6.PubMedCrossRef

18.

Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993;91:1351–7.PubMedCrossRef

19.

Chiang SB, Rebenstock A, Guan L, Alavi A, Zhuang H. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clin Nucl Med. 2003;28:674–6.PubMedCrossRef

20.

Lewanski CR, Kaplan GR, Potter J, Richman P, Ashford RF, Wong WL. Bone marrow involvement in breast cancer detected by positron emission tomography. J R Soc Med. 1999;92:193–5.PubMed

21.

Seshadri N, Wright P, Balan KK. Rhabdomyosarcoma with widespread bone marrow infiltration: beneficial management role of F-18 FDG PET. Clin Nucl Med. 2007;32:787–9.PubMedCrossRef

22.

Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93–8.PubMedCrossRef

23.

Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794–9.PubMed

24.

Morooka M, Kubota K, Murata Y, Shibuya H, Ito K, Mochizuki M, et al. (18)F-FDG-PET/CT findings of granulocyte colony-stimulating factor (G-CSF)-producing lung tumors. Ann Nucl Med. 2008;22:635–9.PubMedCrossRef

25.

Takahashi S, Kuwabara K, Sawafuji M, Akiduki S, Ishizaka A. F-18 FDG PET imaging in a patient with granulocyte colony-stimulating factor producing pulmonary pleomorphic carcinoma. Clin Nucl Med. 2008;33:555–7.PubMedCrossRef

26.

Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin’s lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma. 2004;5:62–4.PubMedCrossRef

27.

Burrell SC, Fischman AJ. Myelofibrosis on F-18 FDG PET imaging. Clin Nucl Med. 2005;30:674.PubMedCrossRef

28.

Inoue K, Okada K, Harigae H, Taki Y, Goto R, Kinomura S, et al. Diffuse bone marrow uptake on F-18 FDG PET in patients with myelodysplastic syndromes. Clin Nucl Med. 2006;31:721–3.PubMedCrossRef

29.

Takalkar A, Yu JQ, Kumar R, Xiu Y, Alavi A, Zhuang H. Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clin Nucl Med. 2004;29:637–9.PubMedCrossRef

Title: A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity
Authors: Kentaro Inoue
Ryoi Goto
Ken Okada
Shigeo Kinomura
Hiroshi Fukuda
Publication date: 01-09-2009
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 7/2009
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-009-0286-9

ACC 2024 Congress

Springer Medicine

A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity

Abstract

Objective

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

Improvement of image quality using interpolated projection data estimation method in SPECT

Diagnostic usefulness of 18F-FDG PET/CT in the differentiation of pulmonary artery sarcoma and pulmonary embolism

Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imaging?

Predictive value of cardiac autonomic indexes and MIBG washout in ICD recipients with mild to moderate heart failure

Predictor of underlying myocardial damage in normally functioning left ventricle with narrow QRS complex: relationship between QRS duration at right ventricle pacing and iodine-123 metaiodobenzylguanidine myocardial scintigraphy

Adverse allergic reaction to 131I MIBG